CRISPR Therapeutics AGCRSPNASDAQ
Loading
Book Value/Share Growth Under PressureDecelerating
Percentile Rank69
5Y CAGR-40.0%
Year-over-Year Change
Year-over-year book value per share growth
5Y CAGR
-40.0%/yr
Long-term compound
Percentile
P69
Within normal range
vs 5Y Ago
0.1x
Contraction
Streak
1 qtr
Consecutive declineDecelerating
| Period | Value |
|---|---|
| Q4 2025 | 1.84% |
| Q3 2025 | 6.78% |
| Q2 2025 | -7.67% |
| Q1 2025 | -5.85% |
| Q4 2024 | -0.66% |
| Q3 2024 | -2.45% |
| Q2 2024 | -8.44% |
| Q1 2024 | 7.83% |
| Q4 2023 | 8.60% |
| Q3 2023 | -5.25% |
| Q2 2023 | -2.61% |
| Q1 2023 | -1.53% |
| Q4 2022 | -4.52% |
| Q3 2022 | -7.14% |
| Q2 2022 | -7.26% |
| Q1 2022 | -6.99% |
| Q4 2021 | -5.15% |
| Q3 2021 | -3.89% |
| Q2 2021 | 42.53% |
| Q1 2021 | 1.54% |
| Q4 2020 | 23.69% |
| Q3 2020 | 29.06% |
| Q2 2020 | 1.70% |
| Q1 2020 | -10.72% |
| Q4 2019 | 51.62% |
| Q3 2019 | 56.16% |
| Q2 2019 | -5.19% |
| Q1 2019 | -4.25% |
| Q4 2018 | -13.53% |
| Q3 2018 | 55.56% |
| Q2 2018 | -10.55% |
| Q1 2018 | 54.57% |
| Q4 2017 | -8.28% |
| Q3 2017 | -9.96% |
| Q2 2017 | -8.47% |
| Q1 2017 | -7.60% |
| Q4 2016 | 472.63% |
| Q3 2016 | -146.20% |
| Q2 2016 | -40.06% |
| Q1 2016 | 671.47% |